AU Stock MarketDetailed Quotes
IMU Imugene Ltd
- 0.082
- +0.003+3.80%
20min DelayNot Open Apr 29 16:00 AET
613.45MMarket Cap-13666P/E (Static)
0.084High0.079Low14.19MVolume0.080Open0.079Pre Close1.17MTurnover0.15052wk High0.24%Turnover Ratio7.48BShares0.03952wk Low-0.013EPS TTM495.31MFloat Cap0.625Historical HighLossP/E (Static)6.04BShs Float0.000Historical Low-0.006EPS LYR6.33%Amplitude--Dividend TTM3.15P/B1Lot Size--Div YieldTTM
About Imugene Ltd Company
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its product includes HER-Vaxx,PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment being the Research and Development of oncolytic immunotherapies.
Company Profile
SymbolIMU
Company NameImugene Ltd
Founded1986
MarketASX
Employees3
Fiscal Year Ends06-30
Address4-6 Bligh Street Suite 12.01, Level 12
CitySydney
CountryAustralia
Zip Code2000
Websitehttps://www.imugene.com
Company Executives
- Name
- Position
- Salary
- Leslie Chong
- Director, Chief Executive Officer and Managing Director
- --
- Paul E Hopper
- Executive Chairman of the Board
- --
- Dr. Kimberlee Cobleigh Drapkin, PhD
- Director
- --
- Dr. Lesley Russell,M.B.,Ch.B.
- Independent Director
- --
- Dr. Jens Eckstein
- Independent Director
- --
- Dr. Jakob Dupont, M.D.
- Independent Director
- --
Analysis
Price Target
No Data
Heat List
AU
Overall
Symbol
Latest Price
%Chg